medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-18-16-22medsovet-2788Research ArticleКОГНИТИВНЫЕ НАРУШЕНИЯ И ДЕМЕНЦИЯCOGNITIVE IMPAIRMENT AND DEMENTIAНейропсихологическая диагностика и лечение пациентов с деменциейNeuropsychological testing in the diagnosis and management of patients with dementiaГришинаД. А.GrishinaD. A.

Гришина Динара Александровна – кандидат медицинских наук, ассистент кафедры нервных болезней и нейрохирургии

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияSechenov First Moscow State Medical University of the Ministry of Health of RussiaRussian Federation2018161120180181622Copyright © Гришина Д.А., 20182018Гришина Д.А.Grishina D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2788

В статье обсуждаются нейропсихологические методы диагностики когнитивных нарушений. Приводятся данные об опыте применения мемантина (Акатинола мемантина) при деменции различного генеза. Анализируется эффективность немедикаментозных методов терапии деменции, включая когнитивный тренинг.

The article discusses neuropsychological tests for diagnosing cognitive impairment. It presents data on the experience in using memantine (akatinol memantine) to treat dementia of various genesis. An analysis of efficacy of non-pharmacological approaches to the treatment of dementia including cognitive training is provided.

когнитивные нарушениядеменциянейропсихологическое обследованиемемантинcognitive impairmentdementianeuropsychological examinationmemantineReferencesЯхно Н.Н. Когнитивные расстройства в неврологической клинике. Неврологический журнал, 2006, 11(S1): 4–12.Yahno NN. Cognitive disorders in the neurological clinic. Nevrologichesky Zhurnal, 2006, 11 (S1): 4–12.Яхно Н.Н., Захаров В.В., Локшина А.Б., Коберская Н.Н., Мхитарян Э.А. Деменции. Практическое руководство для врачей. М.: МЕДпрессинформ, 2011. 272 c.Yakhno NN, Zakharov VV, Lokshina AB, Koberskaya NN, Mkhitaryan EA. Dementia. A practical guide for practitioners. M.: MEDpressinform, 2011. 272 p.Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М.: Ремедиум, 2014.Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Cognitive disorders. M.: Remedium, 2014.Diagnostic and statistical manual of mental diseases. V ed. (DSM-V). London: American Psychiatric Association, 2013.Diagnostic and statistical manual of mental diseases. V ed. (DSM-V). London: American Psychiatric Association, 2013.Яхно Н.Н., Захаров В.В., Коберская Н.Н., Мхитарян Э.А., Гришина Д.А., Локшина А.Б. и др. «Предумеренные» (субъективные и легкие) когнитивные расстройства. Неврологический журнал, 2017, 22(4): 198–204.Yakhno NN, Zakharov VV, Koberskaya NN, Mkhitaryan EA, Grishina DA, Lokshina AB, et al. “Pre-moderate” (subjective and light) cognitive disorders. Nevrologichesky Zhurnal, 2017, 22 (4): 198–204.Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia. London: Alzheimer’s disease international, 2016.Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia. London: Alzheimer’s disease international, 2016.Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журнал, 2006, 11: 27–32.Zakharov VV. All-Russian Program for the Study of Epidemiology and Therapy of Cognitive Disorders in the Elderly (“Prometheus”). Nevrologichesky Zhurnal, 2006, 11: 27–32.Яхно Н.Н., Преображенская И.С., Захаров В.В., Степкина Д.А., Локшина А.Б., Мхитарян Э.А. и др. Распространенность когнитивных нарушений при неврологических заболеваниях (анализ работы специализированного амбулаторного приема). Неврология, нейропсихиатрия, психосоматика, 2012, 2: 30–35.Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Stepkina DA, Lokshina AB, Mkhitaryan EA. The prevalence of cognitive impairment in neurological diseases (analysis of specialized outpatient visits). Nevrologiya, Neyropsikhiatriya, Psikhosomatika, 2012, 2: 30–35.Захаров В.В., Вознесенская Т.Г. Нервно-психические нарушения: диагностические тесты. М.: МЕДпресс-информ, 2013. 320 с.Zakharov VV, Voznesenskaya TG. Neuropsychiatric disorders: diagnostic tests. M.: MEDpress-inform, 2013. 320 p.Левин О.С. Алгоритмы диагностики и лечения деменции. М.: МЕДпресс-информ, 2014. 192 с.Levin OS. Algorithms for the diagnosis and management of dementia. M.: MEDpress-inform, 2014. 192 p.Степкина Д.А., Захаров В.В., Яхно Н.Н. Синдром первичной прогрессирующей афазии. Неврологический журнал, 2014, 5: 22-28.Stepkina DA, Zakharov VV, Yakhno NN. Syndrome of primary progressive aphasia. Nevrologichesky Zhurnal, 2014, 5: 22-28.Парфенов В.А., Старчина Ю.А., Яхно Н.Н. Эпросартан (Теветен) в профилактике повторного инсульта и когнитивных нарушений. Неврологический журнал, 2007, 12(1): 46–51.Parfenov VA, Starchin YuA, Yakhno NN. Eprosartan (Teveten) in the prevention of re-stroke and cognitive impairment. Nevrologichesky Zhurnal, 2007, 12 (1): 46–51.Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. Dementia therapeutic research ed. by K. Rockwood, S. Gauthier. London, New York: Taylor a Francis, 2006: 189–212.Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. Dementia therapeutic research ed. by K. Rockwood, S. Gauthier. London, New York: Taylor a Francis, 2006: 189–212.Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi Ch et al. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy, 2013, 7: 1359-1364.Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi Ch et al. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy, 2013, 7: 1359-1364.Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М.: Пульс, 2003.Gavrilova SI. Pharmacotherapy of Alzheimer’s disease. M.: Pulse, 2003.Дамулин И.В., Яхно Н.Н. Болезнь Альцгеймера и сосудистая деменция. М., 2002. 85 c. /Damulin IV, Yakhno NN. Alzheimer’s disease and vascular dementia. M., 2002. 85 c.Damulin IV, Yakhno NN. Alzheimer’s disease and vascular dementia. M., 2002. 85 c.Levin DA, Langa KM. Vascular cognitive impairment: disease mechanisms and treatment implications. Neurotherapeutics, 2011, 8 (3): 361–73.Levin DA, Langa KM. Vascular cognitive impairment: disease mechanisms and treatment implications. Neurotherapeutics, 2011, 8 (3): 361–73.Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement, 2011, 5: 280-292.Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement, 2011, 5: 280-292.Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacological Reports, 2016, 68(1): 127-138.Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacological Reports, 2016, 68(1): 127-138.Mark LP, Prost RW, Ulmer JL, Smith MM, Daniels DL, Strottmann JM et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. Amer J Neuroradiol, 2001, 22: 1813-1824.Mark LP, Prost RW, Ulmer JL, Smith MM, Daniels DL, Strottmann JM et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. Amer J Neuroradiol, 2001, 22: 1813-1824.Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer’s disease. Neurosci Lett, 1998, 86: 109-113.Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer’s disease. Neurosci Lett, 1998, 86: 109-113.Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 2004, 291: 317-324.Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 2004, 291: 317-324.Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K. et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebocontrolled, multicentre trial. Lancet Neurol, 2009, 8: 613–618.Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K. et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebocontrolled, multicentre trial. Lancet Neurol, 2009, 8: 613–618.Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33: 1834–1839.Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33: 1834–1839.Petersen KA. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology, 2007, 14(1): 1107.Petersen KA. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology, 2007, 14(1): 1107.Яхно Н.Н., Преображенская И.С., Захаров В.В., Мхитарян Э.А. Эффективность мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал, 2010, 2: 52–58.Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. Efficacy of memantine in patients with non-dement cognitive disorders. The results of multicenter clinical observation. Nevrologichesky Zhurnal, 2010, 2: 52–58.Парфенов В.А. Ранняя диагностика и лечение болезни Альцгеймера. Медицинский совет, 2015, 5: 28–33. /Parfenov VA. Early diagnosis and management of Alzheimer’s disease. Meditsinsky Sovet, 2015, 5: 28–33.Parfenov VA. Early diagnosis and management of Alzheimer’s disease. Meditsinsky Sovet, 2015, 5: 28–33.Mendiola-Precoma J, Berumen LC, Padilla K. Therapies for prevention and treatment of Alzheimer’s disease. BioMed research international, 2016: 17.Mendiola-Precoma J, Berumen LC, Padilla K. Therapies for prevention and treatment of Alzheimer’s disease. BioMed research international, 2016: 17.Olazaran J, Muniz R, Reisberg B et al. Benefit of cognitive-motor intervention in MCI and mild-to-moderate AD. Neurology, 2004, 63 (12): 2348–2353.Olazaran J, Muniz R, Reisberg B et al. Benefit of cognitive-motor intervention in MCI and mild-to-moderate AD. Neurology, 2004, 63 (12): 2348–2353.

The authors declare that there are no conflicts of interest present.